vTv Therapeutics Inc
Change company Symbol lookup
Select an option...
VTVT vTv Therapeutics Inc
BUGDF Bumrungrad Hospital PCL
ORCL Oracle Corp
OPTT Ocean Power Technologies Inc
SPEYF Spey Resources Corp
BCTX Briacell Therapeutics Corp
JAZZ Jazz Pharmaceuticals PLC
KRT Karat Packaging Inc
REMRF Red Moon Resources Inc
ARR ARMOUR Residential REIT Inc
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer's disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial. Its type II diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator (GKA), for which it has completed enrollment in its Phase IIb clinical trial, and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (GLP-1r), for which it began enrollment in a Phase II clinical trial. It has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.

Price
Delayed
$2.56
Day's Change
0.20 (8.47%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.83
Day's Low
2.53
Volume
(Heavy Day)

Today's volume of 15,480,832 shares is on pace to be much greater than VTVT's 10-day average volume of 1,787,956 shares.

15,480,832

Display:

Providers:

UpdateCancel
6 providers
Today's News, June 22, 2021
Thinking about buying stock in vTv Therapeutics, Score Media and Gaming, Bio-Path Holdings, Anavex Life Sciences, or Atossa Therapeutics?

InvestorsObserver issues critical PriceWatch Alerts for VTVT, SCR, BPTH, AVXL, and ATOS. https://mma.prnewswire.com/media/1333368/InvestorsObserver_Logo.jpg To see how InvestorsObserver's proprietary scoring system rates these stocks, view the...(PR Newswire)

vTv Therapeutics and Cantex Pharmaceuticals Announce Strategic Licensing Agreement for Development and Commercialization of Azeliragon for Treatment of Cancer

vTv Therapeutics Inc. ("vTv", Nasdaq:VTVT) and Cantex Pharmaceuticals, Inc. ("Cantex") today announced that they have entered into a licensing agreement under which Cantex has obtained exclusive worldwide rights to develop and commercialize...(Globe Newswire)

May 05, 2021
vTv Therapeutics Announces 2021 First Quarter Financial Results and Provides Corporate Update

Awarded Breakthrough Therapy designation for TTP399 for the treatment of type 1 diabetes Initiated two phase 1 clinical studies, mechanistic study of TTP399 and multiple ascending dose study of HPP737 (Globe Newswire)

April 13, 2021
vTv Therapeutics Receives FDA Breakthrough Therapy Designation for TTP399 for the Treatment of Type 1 Diabetes

vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and psoriasis, today announced that the U.S. Food and Drug Administration (FDA) has...(Globe Newswire)

April 12, 2021
TTP399 SimpliciT-1 Study Results to be presented at a scientific symposium in celebration of the 100th anniversary of the discovery of insulin

vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and inflammatory diseases, today announced that results from the JDRF-supported...(Globe Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.